Title: Evidence-based policy or policy-based evidence?

Research on product transitions in a changing nicotine market and the challenges of handing over findings to regulators who actually want different results.

Bio:

Dr. Karl E. Lund is currently senior researcher at the Norwegian Institute of Public Health after serving as Research Director at the Norwegian Institute for Alcohol and Drug Research for the period 2006-2018. He has been involved in tobacco control work since the mid-1980s, working at the Norwegian Council on Tobacco or Health (Deputy Leader), the Norwegian Cancer Society (Director Department of Cancer Prevention) and the University of Oslo. In 2000 dr. Lund received the Norwegian Medical Association’s Award in preventive medicine. Dr. Lund holds a Ph.D. in Sociology from 1996 and he was formally assessed with qualifications as Professor in 2009.

Dr. Lund has been a member of several expert committees including WHO’s International Agency for Cancer Research, he was a founding member of the International Society for the Prevention of Tobacco Induced Diseases and is currently vice president in The International Association on Smoking Control & Harm Reduction. He has been Associate Editor in Nicotine & Tobacco Research since 2011. Dr. Lund chaired the organizing committee for the 19th European SRNT-conference and co-chaired the scientific committee. He co-chaired the Scientific Program Committee of the National French Cancer Research Institute E-cigarette Conference in Paris, 2022.

Dr. Lund has been an expert witness for the plaintiff in several tort liability lawsuits against the tobacco industry including one brought before the Norwegian Supreme Court. He has given expert witness statements in additional court cases, including one before the UK High Court of Justice and one in the European Court of Justice. He has received grants from the Research Council of Norway, from the Norwegian Cancer Society and from diverse National governmental funding sources.